[1] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志, 2007, 46(10): 876-882. DOI:10. 3760/j.issn:0578-1426. 2007. 10. 035.
Drafting Group of the Chinese Medical Association Endocrinology Branch China. China thyroid disease treatment guidelines—hyperthyroidism[J]. Chin J Intern Med, 2007, 46(10): 876-882.  doi: 10.3760/j.issn:0578-1426.2007.10.035
[2] 中华医学会核医学分会. 131I治疗格雷夫斯甲亢指南(2013版)[J].标记免疫分析与临床, 2014, 21(1):92-104. DOI:10.11748/bjmy.issn.1006－1703.2014.01.030.
Chinese Society of Nuclear Medicine. 131I treatment of Graves′ hyperthyroidism Guide(2013 Edition)[J]. Labeled Immunoassays & Clin Med, 2014, 21(1): 92-104.  doi: 10.11748/bjmy.issn.1006－1703.2014.01.030
[3] 万芳, 林秋玉, 赵红光, 等. 131I治疗甲状腺功能亢进症的研究进展[J].吉林大学学报:医学版, 2013, 39(4): 851-854. DOI:10. 7694/jldxyxb20130444.
WanF, Lin QY, Zhao HG, et al. Advanced research on 131I in treatment of hyperthyroidism[J]. J Jilin Univ(Med Edit), 2013, 39(4): 851-854.  doi: 10.7694/jldxyxb20130444
[4] 蒋宁一, 匡安仁, 谭建, 等. 131I治疗Graves甲亢专家共识(2010年)[J].中华核医学杂志, 2010, 30(5): 346-351. DOI:10. 3760/cma.j.issn. 0253-9780. 2010. 05. 019.
Jiang NY, Kuang AR, Tan J, et al. 131I therapy for Graves hyperthyroidism expert consensus(2010)[J]. Chin J Nucl Med, 2010, 30(5): 346-351.  doi: 10.3760/cma.j.issn.0253-9780.2010.05.019
[5] 徐志勇, 周嘉强. 131I治疗甲状腺疾病进展[J].全科医学临床与教育, 2012, 10(2): 170-172. DOI:10.3969/j.issn.1672-3686. 2012. 02. 016.
Xu ZY, Zhou JQ. 131I thyroid disease progression treatment[J]. Clin Edu Gen Prac, 2012, 10(2): 170-172.  doi: 10.3969/j.issn.1672-3686.2012.02.016
[6]

张永学, 黄钢.核医学[M]. 2版.北京:人民卫生出版社, 2010: 209-233.

Zhang YX, Huang G. Nuclear Medicine[M]. 2nd ed. Beijing:People′s Medical Publishing House, 2010: 209-233.
[7] 武海明, 谭天秩, 匡安仁, 等. 131I治疗Graves甲亢疗效影响因素的研究[J].中华核医学杂志, 2003, 23(5): 291, 293. DOI:10. 3760/cma.j.issn. 2095-2848. 2003. 05. 024.
Wu HM, Tan TZ, Kuang AR, et al. 131I treatment of hyperthyroidism Efficacy Study of Factors Affecting Graves[J]. Chin J Nucl Med, 2003, 23(5): 291, 293.  doi: 10.3760/cma.j.issn.2095-2848.2003.05.024
[8] 田志远, 田丽霞, 付秀玲, 等.影响131I首次治疗甲状腺功能亢进症疗效因素分析[J].中华实用诊断与治疗杂志, 2010, 24(2): 206-207.
Tian ZY, Tian LX, Fu XL, et al. Effect 131I Hyperthyroidism first treatment efficacy factors[J]. J Chin Pract Diagn Ther, 2010, 24(2): 206-207.
[9] Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J]. Thyroid, 2011, 21(6): 593-646. DOI:10. 1089/thy. 2010. 0417.
[10]

马寄晓, 刘秀杰, 何作祥.实用临床核医学[M]. 3版.北京:中国原子能出版社, 2012: 288-293.

Ma JX, Liu XJ, He ZX. Practical clinical nuclear medicine[M]. 3rd ed. Beijing:China Atomic Energy Press, 2012: 288-293.
[11]

李少林, 王荣福.核医学[M]. 7版.北京:人民卫生出版社, 2008: 262.

Li SL, Wang RF. Nuclear Medicine[M]. 7th ed. Beijing:People′s Medical Publishing House, 2008: 262.
[12] 傅宏亮, 杜学亮, 李佳宁, 等.计算剂量方案行格雷夫斯病甲状腺功能亢进放射性碘治疗的疗效分析[J].上海交通大学学报(医学版), 2014, 34(7): 1039-1042. DOI:10. 3969/j.issn. 1674-8115. 2014. 07. 016.
Fu HL, Du XL, Li JN, et al. Calculate dosage regimen row Graves′ disease hyperthyroidism radioactive iodine treatment efficacy[J]. Shanghai Jiaotong Univ(Med Edit), 2014, 34(7): 1039-1042.  doi: 10.3969/j.issn.1674-8115.2014.07.016
[13] 武海明, 谭天秩, 匡安仁, 等. 131I治疗Graves甲亢近期疗效评价[J].山西医科大学学报, 2002, 33(6): 532-533. DOI:10. 3969/j.issn. 1007-6611. 2002. 06. 021.
Wu HM, Tan TZ, Kuang AR, et al. Short-term effects of radioiodine treatment on Graves′ hyperthyroidism[J]. J Shanxi Med Univ, 2002, 33(6): 532-533.  doi: 10.3969/j.issn.1007-6611.2002.06.021
[14] Alexander EK, Larsen PR. High dose of 131I therapy for the treatment of hyperthyroidism caused by Graves′ disease[J]. J Clin Endocrinol Metab, 2002, 87(3): 1073-1077. DOI:10. 1210/jcem. 87. 3. 8333.